Food & Drug Administration (2025) Your guide to FDA-approved medicines that contain semaglutide, Novo Nordisk FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, U.S
No one in the GLP-1 group experienced significant gastrointestinal adverse events during the study, and none discontinued GLP-1 use
As long as you're experiencing overall reduced appetite compared to before treatment, this variation is normal
A second consideration is the potential for altered insulin dynamics
Tirzepatide must be stored at 28C
Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements